Skip to main content

Genitourinary Cancers

September Is Prostate Cancer Awareness Month: What You Can Do to Support Your Patients
Patient Advocacy, Prostate Cancer, Genitourinary Cancers
September 2023, Vol 13, No 9
According to the American Cancer Society, approximately 288,300 men in the United States will be diagnosed with prostate cancer in 2023 and 34,700 deaths will be attributed to the disease. September is Prostate Cancer Awareness Month, a time designated to help people learn more about the disease and to support those who are affected. Read More ›
FDA Approves Lynparza Plus Zytiga and Prednisone (or Prednisolone) for BRCA–Mutated Metastatic Castration-Resistant Prostate Cancer
FDA Approvals, News & Updates, Prostate Cancer, Genitourinary Cancers
July 2023, Vol 13, No 7
On May 31, 2023, the FDA approved a new indication for olaparib (Lynparza; AstraZeneca), a poly (ADP-ribose) polymerase inhibitor, in combination with abiraterone (Zytiga; Astellas) and prednisone (or prednisolone) for adults with deleterious or suspected deleterious BRCA mutation–positive, metastatic castration-resistant prostate cancer as determined by an FDA-approved test. Read More ›
Optimal Systemic Therapy for Renal Cell Carcinoma Is Still Evolving
By William King
NCCN 2023 Conference Highlights, Renal-Cell Carcinoma, Genitourinary Cancers, National Comprehensive Cancer Network (NCCN)
May 2023, Vol 13, No 5
Surgery is typically the gold standard for patients with biopsy-proven, clear cell, renal cell carcinoma with no evidence of metastatic disease, said Eric Jonasch, MD, in a session during the 2023 National Comprehensive Cancer Network Conference. In this setting, there is probably not a role for systemic neoadjuvant treatment, as response rates of 15% to 45% have been recorded with axitinib (Inlyta), sunitinib (Sutent), and other tyrosine kinase inhibitors. Read More ›
FDA Grants Padcev plus Keytruda Accelerated Approval for Locally Advanced or Metastatic Urothelial Carcinoma
FDA Approvals, News & Updates, Urothelial Cancer, Genitourinary Cancers
May 2023, Vol 13, No 5
On April 3, 2023, the FDA accelerated the approval of a new indication for enfortumab vedotin-ejfv (Padcev; Astellas Pharma), a Nectin-4–directed antibody and microtubule inhibitor conjugate, with pembrolizumab (Keytruda; Merck), a PD-1 inhibitor, for patients with locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin-containing chemotherapy. Read More ›
Adstiladrin, First Adenoviral Vector–Based Gene Therapy, FDA Approved for High-Risk Non–Muscle-Invasive Bladder Cancer
FDA Approvals, News & Updates, Bladder Cancer, Genitourinary Cancers
March 2023, Vol 13, No 3
On December 16, 2022, the FDA granted approval to nadofaragene firadenovec-vncg (Adstiladrin; Ferring Pharmaceuticals), a nonreplicating adenoviral vector–based gene therapy, for adults with high-risk Bacillus Calmette-Guérin (BCG) unresponsive non–muscle-invasive bladder cancer (NMIBC) and carcinoma in situ, with or without papillary tumors. The FDA granted this indication breakthrough therapy and orphan drug designations. Read More ›
A Call to Focus on Financial Toxicity and Quality of Life in Genitourinary Malignancies
By Wayne Kuznar
Genitourinary Cancers, ASCO 2020 Highlights
April 2020, Vol 10, No 4

Delivering the keynote address at the 2020 Genitourinary Cancers Symposium, David F. Penson, MD, MPH, MMHC, Hamilton and Howd Chair in Urologic Oncology, Vanderbilt University Medical Center, Nashville, TN, highlighted the need to move toward patient-centered decisions beyond survival, focusing on patient-centered outcomes by integrating quality of life (QOL) and financial toxicity into the shared, treatment-related, decision-making process.

Read More ›
De-escalating Chemotherapy Possible in Low-Risk Patients with Advanced Testicular Cancer
By Wayne Kuznar
Genitourinary Cancers, ASCO 2020 Highlights
April 2020, Vol 10, No 4

De-escalating chemotherapy based on a negative positron-emission tomography (PET) scan after 2 cycles of treatment is safe and feasible in most patients with low-volume metastatic seminoma, the most common type of testicular cancer, according to results presented at the 2020 Genitourinary Cancers Symposium.

Read More ›